Antibiotic Resistance Flashcards
(48 cards)
Mechanisms of antibiotic resistance
Active efflux
Target bypass
Target site modification
Decreased influx
Inactivation of antibiotic
Target protection
Active efflux
Pumps facilitate the movement of antibiotic out of cell
Active efflux pump families
ABC
MFS
SMR
RND
MATE
ABC transporter family
contains both uptake and efflux transport systems. The members of this family are unique in that they use energy derived from ATP hydrolysis.
These pumps transport amino acids, drugs, ions, polysaccharides, proteins, and sugars.
Bacterial ABC transporters usually are made up of six transmembrane segments (TMS) consisting of α-helices, function in the membrane in pairs, either as homodimers or heterodimers, and work in conjunction with cytoplasmic ATPases.
These pumps have fairly specific substrates, and there are very few found in clinically significant bacteria.
One notable ABC pump is found in Vibrio cholerae (VcaM), and is capable of transporting fluoroquinolones and tetracycline
MATE transporter family
use a Na+ gradient as the energy source, and efflux cationic dyes, and most efflux fluoroquinolone drugs.
Some MATE pumps have also been shown to efflux some aminoglycosides. Other substrates for these pumps may have unrelated chemical structures.
These pumps are made up of twelve TMS.
Very few of these have been characterized in bacteria, and most are found in gram negative organisms.
MFS transporter family
catalyze transport via solute/cation (H+ or Na+) symport or solute/H+ antiport. They are involved in the transport of anions, drugs (e.g. macrolides and tetracycline), metabolites (e.g. bile salts), and sugars. The MFS pumps have the greatest substrate diversity as a group, yet individually tend to be substrate specific.
Examples of this substrate specificity include Acinetobacter baumannii having separate MFS pumps for erythromycin (SmvA) and chloramphenicol (CraA and CmlA), and Escherichia coli having separate MFS pumps for macrolides (MefB), fluoroquinolones (QepA), and trimethoprim (Fsr). There are rare examples of MFS pumps with a slightly broader substrate specificity, such as in the NorA pump in Staphylococcus aureus which transports fluoroquinolones and chloramphenicol (these antimicrobials are the most commonly transported by MFS pumps), or the S. aureus LmrS pump which transports linezolid, erythromycin, chloramphenicol, and trimethoprim. These pumps are made up of twelve or fourteen TMS, and over 1,000 have been sequenced in bacteria. Most MFS pumps have been found on bacterial chromosomes, and nearly 50% of the efflux pumps in E. coli are MFS pumps
SMR transporter family
energized by the proton-motive force (H+), are hydrophobic, and efflux mainly lipophilic cations, so may have a very narrow substrate range.
The genes for these pumps have been found in chromosomal DNA and on plasmids and transposable elements. These pumps are made up of four TMS and function as asymmetrical homotetramers.
Drug efflux has only been seen in a few of these pumps, and these most commonly confer resistance to β-lactams and some aminoglycosides. Examples of SMR pumps are seen in Staphylococcus epidermidis (the SMR pump which transports ampicillin, erythromycin and tetracycline) and Escherichia coli (the EmeR pump which transports vancomycin, erythromycin, and tetracycline).
RND transporter family
catalyze substrate efflux via a substrate/H+ antiport mechanism, and are found in numerous gram negative bacteria. They are involved in the efflux of antibiotics (all are multi-drug transporters), detergents, dyes, heavy metals, solvents, and many other substrates. Some of these pumps may be drug or drug class specific (Tet pump—tetracycline; Mef pump—macrolides). Many other RND pumps are capable of transporting a wide range of drugs, such as the MexAB-OprM pump in Pseudomonas aeruginosa that confers intrinsic resistance to β-lactams, chloramphenicol, tetracycline, trimethoprim, sulfamethoxazole, and some fluoroquinolones. These pumps are complex multi-component pumps generally made up of twelve TMS and contain two large periplasmic loops between TMS 1 and 2, and TMS 7 and 8. In order to function, these pumps will connect to an OMP and that connection is stabilized by MFPs. Interestingly, these pumps share a high degree of homology among the RND members. The genes for the RND pumps are generally organized as an operon. In many, the gene organization is as follows: the gene for the regulator (which may be transcribed in the opposite direction to the other genes) is adjacent to the MFP gene, which is adjacent to the main pump gene, and then the OMP gene. Probably the most widely studied RND pump is the AcrAB-TolC pump in Escherichia coli, which confers resistance to penicillins, chloramphenicol, macrolides, fluoroquinolones, and tetracycline. The AcrB pump protein contains two binding pockets which allow the binding of substrates of varying size and chemical properties
Beta lactamases
Enzymes
Resistance against beta lactams by hydrolysis of amide bond in the beta-lactam ring
Clavulanic acid
Beta lactamase inhibitor
Specific RNA methyltransferases
Protect the target site from aminoglycoside binding
MfpA
blocks gyrase’s ability to twist and untwist DNA.
By binding to gyrase in DNA’s place, MfpA apparently deprives fluoroquinolones of their target; the drugs bind to gyrase-DNA complexes rather than to just the enzyme. MfpA’s inhibition of gyrase function probably slows the bacteria down, but it’s better than being killed by fluoroquinolones.
Which efflux pumps pump H+ into the cell
MFS
SMR
RND
Which efflux pump uses Na+ into the cell
MATE
Which efflux pump requires ATP
ABC
Which efflux pump spans both inner and outer membrane
RND
Target site alteration
involves alteration of the antibiotic target to reduce binding of the antibiotic.
This can involve mutations in the gene encoding the protein target of the antibiotic molecule or enzymatic alteration of the binding site
Target bypass
the function of the antibiotic target is accomplished by a new protein that is not inhibited by the antibiotic, making the original target redundant and the antibiotic ineffective
Decreased influx
mediated by changes to membrane structure, for example, the downregulation of porins, which are transmembrane proteins that allow the passive transport of various compounds, such as antibiotics, into the bacterial cell
Target protection
generally involves the physical association of a target protection protein with the antibiotic target, thereby relieving it from antibiotic-mediated inhibition
Mechanisms of target bypass
The drug target (such as an enzyme) becomes redundant due to acquisition of a gene that encodes an alternative enzyme that fulfils the function of the drug target
The drug target can be replaced by an alternative target that sequesters the drug, thereby allowing the drug target to resume its function
The drug target can be overproduced and thus there is insufficient amount of drug to inhibit the increased available target
Mechanisms of drug alteration
Enzymes can hydrolyse the functional group of the drug, thereby destroying its antibacterial activity
Enzymes (such as acetyltransferases, methyltransferases or phosphotransferases) can modify the drug by covalent transfer of various chemical groups to prevent it from binding its target
Mechanisms of target protection
Target protection proteins can bind to the drug target and sterically remove the drug from the target
Target protection proteins can bind to the drug target and mediate allosteric dissociation of the drug from its target
Target protection proteins can bind to the drug target and cause conformational changes to allow the target protein to function even in the presence of the drug